期刊
CANCERS
卷 6, 期 2, 页码 1098-1110出版社
MDPI
DOI: 10.3390/cancers6021098
关键词
CCL21; cancer immunotherapy; dendritic cell; polymer; T cell
类别
资金
- American Academy of Otolaryngology-American Head & Neck Society Surgeon Scientist Career Development Award
- Tobacco-Related Disease Research Program of the University of California
- STOP Cancer Foundation
- Jonsson Cancer Center
- NIDCR K23
- Department of Veterans Affairs Medical Research Funds
- National Institutes of Health (NIH) Grants [RO1 CA126944]
- Tobacco Related Disease Program Award Program of University of California [15RT-0207, 20FT0082]
Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据